Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies
Research on cancer therapies focuses on processes such as angiogenesis, cell signaling, stemness, metastasis, and drug resistance and inflammation, all of which are influenced by the cellular and molecular microenvironment of the tumor. Different strategies, such as antibodies, small chemicals, horm...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/15/4539 |
| _version_ | 1797441702752944128 |
|---|---|
| author | Virginia Albiñana Eunate Gallardo-Vara Juan Casado-Vela Lucía Recio-Poveda Luisa María Botella Angel M Cuesta |
| author_facet | Virginia Albiñana Eunate Gallardo-Vara Juan Casado-Vela Lucía Recio-Poveda Luisa María Botella Angel M Cuesta |
| author_sort | Virginia Albiñana |
| collection | DOAJ |
| description | Research on cancer therapies focuses on processes such as angiogenesis, cell signaling, stemness, metastasis, and drug resistance and inflammation, all of which are influenced by the cellular and molecular microenvironment of the tumor. Different strategies, such as antibodies, small chemicals, hormones, cytokines, and, recently, gene editing techniques, have been tested to reduce the malignancy and generate a harmful microenvironment for the tumor. Few therapeutic agents have shown benefits when administered alone, but a few more have demonstrated clear improvement when administered in combination with other therapeutic molecules. In 2008 (and for the first time in the clinic), the therapeutic benefits of the β-adrenergic receptor antagonist, propranolol, were described in benign tumors, such as infantile hemangioma. Propranolol, initially prescribed for high blood pressure, irregular heart rate, essential tremor, and anxiety, has shown, in the last decade, increasing evidence of its antitumoral properties in more than a dozen different types of cancer. Moreover, the use of propranolol in combination therapies with other drugs has shown synergistic antitumor effects. This review highlights the clinical trials in which propranolol is taking part as adjuvant therapy at single administration or in combinatorial human trials, arising as a good pick and roll partner in anticancer strategies. |
| first_indexed | 2024-03-09T12:27:00Z |
| format | Article |
| id | doaj.art-a3c8a8e4022f46798192fc608fe5a76a |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T12:27:00Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-a3c8a8e4022f46798192fc608fe5a76a2023-11-30T22:33:49ZengMDPI AGJournal of Clinical Medicine2077-03832022-08-011115453910.3390/jcm11154539Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer TherapiesVirginia Albiñana0Eunate Gallardo-Vara1Juan Casado-Vela2Lucía Recio-Poveda3Luisa María Botella4Angel M Cuesta5Centro de Investigaciones Biológicas Margaritas Salas, 28040 Madrid, SpainYale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, 300 George Street, New Haven, CT 06511, USADepartamento Bioingeniería, Escuela Politécnica Superior, Universidad Carlos III de Madrid, Av. de la Universidad, 30, 28911 Leganés, SpainCentro de Investigaciones Biológicas Margaritas Salas, 28040 Madrid, SpainCentro de Investigaciones Biológicas Margaritas Salas, 28040 Madrid, SpainCIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, Unidad 707, Instituto de Salud Carlos III (ISCIII), 28029 Madrid, SpainResearch on cancer therapies focuses on processes such as angiogenesis, cell signaling, stemness, metastasis, and drug resistance and inflammation, all of which are influenced by the cellular and molecular microenvironment of the tumor. Different strategies, such as antibodies, small chemicals, hormones, cytokines, and, recently, gene editing techniques, have been tested to reduce the malignancy and generate a harmful microenvironment for the tumor. Few therapeutic agents have shown benefits when administered alone, but a few more have demonstrated clear improvement when administered in combination with other therapeutic molecules. In 2008 (and for the first time in the clinic), the therapeutic benefits of the β-adrenergic receptor antagonist, propranolol, were described in benign tumors, such as infantile hemangioma. Propranolol, initially prescribed for high blood pressure, irregular heart rate, essential tremor, and anxiety, has shown, in the last decade, increasing evidence of its antitumoral properties in more than a dozen different types of cancer. Moreover, the use of propranolol in combination therapies with other drugs has shown synergistic antitumor effects. This review highlights the clinical trials in which propranolol is taking part as adjuvant therapy at single administration or in combinatorial human trials, arising as a good pick and roll partner in anticancer strategies.https://www.mdpi.com/2077-0383/11/15/4539beta-adrenergic receptor antagonistpropranololchemotherapycombination cancer therapyHIFapoptosis |
| spellingShingle | Virginia Albiñana Eunate Gallardo-Vara Juan Casado-Vela Lucía Recio-Poveda Luisa María Botella Angel M Cuesta Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies Journal of Clinical Medicine beta-adrenergic receptor antagonist propranolol chemotherapy combination cancer therapy HIF apoptosis |
| title | Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies |
| title_full | Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies |
| title_fullStr | Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies |
| title_full_unstemmed | Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies |
| title_short | Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies |
| title_sort | propranolol a pick and roll team player in benign tumors and cancer therapies |
| topic | beta-adrenergic receptor antagonist propranolol chemotherapy combination cancer therapy HIF apoptosis |
| url | https://www.mdpi.com/2077-0383/11/15/4539 |
| work_keys_str_mv | AT virginiaalbinana propranololapickandrollteamplayerinbenigntumorsandcancertherapies AT eunategallardovara propranololapickandrollteamplayerinbenigntumorsandcancertherapies AT juancasadovela propranololapickandrollteamplayerinbenigntumorsandcancertherapies AT luciareciopoveda propranololapickandrollteamplayerinbenigntumorsandcancertherapies AT luisamariabotella propranololapickandrollteamplayerinbenigntumorsandcancertherapies AT angelmcuesta propranololapickandrollteamplayerinbenigntumorsandcancertherapies |